-
By Marlene Y. Satter, AdvisorOne |
May 9, 2013
The decision by an Indian court not to grant a new patent to drug firm Novartis for a modified form of its cancer drug Glivec was a heavy blow to the company.
-
By Janet Levaux, AdvisorOne |
March 1, 2009
--- Alexandra Hauber J.P. Morgan 312-325-3694 Alexandra.m.hauber@jpmorgan.com We expect currency to have a significant impact on 2009 earnings. The biggest effect, due to the British pound weakness, is likely at...
-
By Staff Writer |
August 25, 2003
S&P Rank: 4 Stars Aug. 14, 2003 On the Cusp of a New Drug Boom Quick Take: Drug and biotech stocks suffered in 2002, hurt by poor earnings,...